Salvage treatment of advanced colorectal cancer patients has not been well defined as yet, and new potentially active drugs or combinations should be evaluated for these situations.
Methods
From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. The CBDCA+VP-16 treatment was repeated every 3 weeks. A total of 58 cycles was administered, and 16 patients were evaluable for response.
Results
There was no objective response, but 2 stable diseases and 14 progressive diseases were observed. Toxicity was mild, with no WHO 3–4 grade toxicity.
Conclusion
this combination chemotherapy was judged ineffective for pretreated colorectal cancer patients.
Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896–903, 1992.
2.
ArdalanB., DonofrioK., SridharK.S., BenedettoP., WaldmanS., RichmanS., ReddyR., LivingstoneA.: A phase II study of short term protracted infusion of high-dose 5-fluorouracil (5-FU) with leucovorin (LV) and low dose phosphonacetyl-L-aspartic acid (PALA) in treated and untreated colorectal carcinoma. Proc. Am. Soc. Clin. Oncol., 12: 201, 1993.
3.
BajettaE., ColleoniM., Di BartolomeoM., NolèF., NelliP., DociR., de BraudF., Gallo StampinoC.: Doxofluridine: an active agent in advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol., 13: 192, 1994.
4.
BracardaS., RoilaF., CrinòL., BasurtoC., CiccareseG., PalladinoM.A., MeacciM., TonatoM.: Cisplatin (CDDP), 5-fluorouracil (5-FU), folinic acid (FA) and r-interferon-alpha-2a in advanced colorectal carcinoma. A phase II study. Ann. Oncol., 3 (suppl. 5): 18, 1992.
5.
BugatR., RougierP., BecouarnY., IbrahimN., YchouM., CulineS., ExtraJ.M., AdenisA., GanemG., GiovanniniM., MerroucheM., FerreroJ.F., ConroyT., DespaxR., MousseauM., SucE., Mathieu-BouéA., MahjoubiM., HeraitP.: Irinotecan (CPT-11) is an effective agent in pretreated colorectal cancer (CRC): preliminary results of multicentric phase II study. Ann. Oncol., 5 (suppl. 8): 188–189, 1994.
6.
BunnP.A.: Carboplatin: current status and future directions. In: Carboplatin (JM-S): Current Perspectives and Future Directions, BunnP.A., CanettaR., OzolsR.F., RozencweigM. (eds.), pp. 371–381, WB Saunders, Philadelphia, 1990.
7.
ContiJ.A., KemenyN., GokerE., TongW., ColofioreJ., AndreM., RagusaK., BertinoJ.R.: A phase I trial of sequential trimetrexate (TMTX), fluorouracil (FU) and high-dose leucovorin (LV) in previously treated patients with gastrointestinal (GI) carcinoma. Proc. Am. Soc. Clin. Oncol., 12: 194, 1993.
8.
De GramontA., LouvetC., VaretteC., DemuynckB., BennamounM., CadyJ., GrangéJ.D., LagadecB., MaisaniJ.E., DelfauS., ChazouilleresO., LoiseauJ.P., SerokaJ., KrulikM.: Reversal of resistance to high-dose folinic acid (LV) and 5-fluorouracil (5FU) in metastatic colorectal cancer by hydroxyurea. Proc. Am. Soc. Clin. Oncol., 11: 178, 1992.
9.
Di PlamaM., PaveseI., D'AndreaG., LanzillottaS., MiglioreA., CoiroG.: Octreotide, carboplatino ed etoposide nel carcinoma del colon avanzato. Tumori, 78 (suppl): 90, 1992.
10.
JeremicB., AcimovicLj., DjuricLj., MijatovicLj.: Carboplatin and etoposide in advanced colorectal cancer. A phase II study. Ann. Oncol., 3 (suppl. 5): 21, 1992.
11.
LeongL., DoroshowJ., AkmanS., CarrB., MargolinK., MorganR., RaschkoJ., SomloG.: Phase II trial of 5-FU and high dose folinic acid (FDFA) with cis-platin (CDDP) and dipyridamole (DP) in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 8: 99, 1989.
12.
LeviP., BrienzaS., MissetJ.L., AdamS., KunstlingerF., MetzgerG., Depres-BrummerP., Le CouturierS., ValoriV., MaoudjE., GastiaburuJ., JasminC., BismuthH.: Circumvention of clinical resistance of metastatic colorectal cancer to 5-fluorouracil (5-FU) with circadian-rhythm modulated venous chemotherapy. Proc. Am. Soc. Clin. Oncol., 11: 171, 1992.
13.
LeviF., PerpointB., GarufiC., FocanCh., CholletPh., Depres-BrummerP., ZidaniR., BrienzaS., ItzhakiM., IacobelliS., KunstlingerF., GastiaburuJ., MissetJ.L.: Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer, 29: 1280–1284, 1993.
14.
MarshJ.C., DavisC., O'HallorenK., DuvirageH., VoynickI., PasqualeD., SimonichS., BertinoJ.R.: Phase II study of 5-fluoro-2-deoxiuridine (FUdR) and leucovorin (LV) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 7: 107, 1988.
15.
MillerA.B., HoogstratenB., StaquetM.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
16.
NolèF., BiganzoliL., BuzzoniR., BajettaE.: Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines. Eur. J. Cancer., 29A: 1330–1331, 1993.
17.
PassalacquaR., BisagniG., CocconiG., BoniC., Di BlasioB., CeciG.: Cisplatin and etoposide in advanced colorectal cancer. Ann. Oncol., 2: 687–688, 1991.
18.
PazdurR.D., SamsonM.K., BackerL.H.: CBDCA phase II evaluation in advanced colorectal carcinoma. Am. J. Clin. Oncol., 12: 416–419, 1989.
19.
PitotH.C., WenderD., O'ConnellM.J., WieandH.S., MaillardJ.A.: A phase II trial of CPT-11 (Irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc. Am. Soc. Clin. Oncol., 13: 197, 1994.
20.
RothenbergM.L., EckardtJ.R., BurrisH.A.III, NelsonJ., KuhnJ.G., ChenS.F., HilsenbeckS.G., ClarkG.M., FieldsS.M., RodriguezG.I., WeissG.R., SmithL.S., ThurmanA.M., EckhardtS.G., RinaldD.A., PerezA., von HoffD.D.: Irinotecan (CPT-11) as second-line therapy for pts with 5-FU-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol., 13: 198, 1994.
21.
SchmollH.J., WilkeH., SchoberC.H., StahlM.: High-dose folinic acid (HDFA)/5-fluorouracil (FU)/dipyridamole (DP)-salvage after HDFA/FU failure in colorectal cancer: a phase I study. Proc. Am. Soc. Clin. Oncol., 7: 114, 1988.
22.
SchmollH.J., GundersenS., ArnoldA., NysG., GrattonR., CanettaR.: Phase II study of carboplatin in colorectal cancer. Ann. Oncol., 1 (suppl): 48, 1990.
